当前位置: X-MOL 学术Nat. Rev. Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Gut microbiota injury in allogeneic haematopoietic stem cell transplantation.
Nature Reviews Cancer ( IF 78.5 ) Pub Date : 2018-02-16 , DOI: 10.1038/nrc.2018.10
Yusuke Shono 1, 2 , Marcel R M van den Brink 1, 3, 4
Affiliation  

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is considered to be the strongest curative immunotherapy for various malignancies (primarily, but not limited to, haematologic malignancies). However, application of allo-HSCT is limited owing to its life-threatening major complications, such as graft-versus-host disease (GVHD), relapse and infections. Recent advances in large-scale DNA sequencing technology have facilitated rapid identification of the microorganisms that make up the microbiota and evaluation of their interactions with host immunity in various diseases, including cancer. This has resulted in renewed interest regarding the role of the intestinal flora in patients with haematopoietic malignancies who have received an allo-HSCT and in whether the microbiota affects clinical outcomes, including GVHD, relapse, infections and transplant-related mortality. In this Review, we discuss the potential role of intestinal microbiota in these major complications after allo-HSCT, summarize clinical trials evaluating the microbiota in patients who have received allo-HSCT and discuss how further studies of the microbiota could inform the development of strategies that improve outcomes of allo-HSCT.



中文翻译:

异基因造血干细胞移植中肠道菌群的损伤。

异基因造血干细胞移植(allo-HSCT)被认为是针对各种恶性肿瘤(主要但不限于血液恶性肿瘤)的最强治愈性免疫疗法。然而,由于异体-HSCT危及生命的主要并发症,例如移植物抗宿主病(GVHD),复发和感染,因此其应用受到限制。大规模DNA测序技术的最新进展促进了对构成微生物群的微生物的快速鉴定,并促进了它们与包括癌症在内的各种疾病中宿主免疫的相互作用的评估。这引起了人们对于肠菌群在接受异基因-HSCT的造血系统恶性肿瘤中的作用以及微生物群是否会影响包括GVHD,复发,感染和与移植相关的死亡率。在本综述中,我们讨论了异基因HSCT后肠道菌群在这些主要并发症中的潜在作用,总结了评估接受异源HSCT的患者中菌群的临床试验,并讨论了如何进一步研究菌群可以为制定策略提供参考。改善同种异体造血干细胞移植的结果。

更新日期:2018-02-16
down
wechat
bug